(92 days)
Not Found
No
The device description and performance studies focus on the material properties and clinical outcomes of a vascular prosthesis, with no mention of AI or ML.
Yes
The device is used for the replacement or repair of diseased arteries, which directly treats a medical condition.
No
Explanation: The device is a vascular prosthesis intended for the replacement or repair of arteries, which is a therapeutic function, not a diagnostic one.
No
The device description clearly states it is a "knitted/woven tubular polyester fabric, impregnated with bovine collagen," which is a physical, implantable medical device, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the "replacement or repair of arteries affected with aneurismal or occlusive disease." This is a surgical procedure performed directly on the patient's body.
- Device Description: The device is a "knitted/woven tubular polyester fabric, impregnated with bovine collagen." This describes a physical implant used in surgery.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens derived from the human body (like blood, urine, tissue, etc.) to provide information for diagnosis, monitoring, or screening.
IVD devices are used in vitro (outside the body) to analyze samples. This device is used in vivo (inside the body) as a surgical implant.
N/A
Intended Use / Indications for Use
The AlboGraft Double Velour Knitted and Woven Grafts are indicated for use in the replacement or repair of arteries affected with aneurysmal or occlusive disease.
Product codes (comma separated list FDA assigned to the subject device)
MAL
Device Description
Albograft Vascular Prosthesis is a knitted/woven tubular polyester fabric, impregnated with bovine collagen.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Arteries; iliac region (prox. anastomosis - common iliac artery / distal anastomosis - proximal superficial femoral artery)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Summary of Product Testing:
The following tests have been performed per ISO 7198:
Burst Test
Longitudinal Tensile Strength
Radial Tensile Strength
Suture Pull-90°/45°
Wall Thickness
Integral Water Permeability
Visual Inspection
Usable Length
Relaxed Inner Diameter
Pressurized Inner Diameter
Summary of Pre-clinical Study:
The biocompatibility of the device was tested per ISO10993-1.
Summary of Retrospective Clinical Review:
Patient baseline data, preoperative risk factors, diagnosis and secondary diseases:
Between Jan 1, 2007 and March 31, 2009, 66 consecutive patients have received a surgical implant of a peripheral AlboGraft vascular prosthesis in the iliac region (prox. anastomosis - common iliac artery / distal anastomosis - proximal superficial femoral artery). The patients consisted mainly of males (n= 44 / 66 %) with a mean age of 64.8 years (Mean: H: 171 cm; W: 74 kg; BMI: 25.2 kg/cm²) and demonstrated typical risk factors for development of illiac artery peripheral arterial occlusive disease (pAOD).
The majority of patients (88%) suffered from arterial hypertension and histories of smoking in 92% of the cases (73% of all patients are still active smokers). Almost half (49 %) of the patients had additional coronary heart disease, while additional risk factors like diabetes mellitus or hyperlipidemia was only present in 9% or 3% of the patients respectively. Chronic obstructive pulmonary disease was present in 29% of the patients and cerebro vascular disease in n= 10 (15%) of which n=8 had a previous stroke. Also almost half of the patients (49%) had previous arterial reconstructions.
Disease / Diagnosis:
4 patient suffered from aneurysmal disease (n=2 iliac artery aneurysms; n=2 suture line aneurysms) and 62 patients reported pAOD of the iliac artery with either severe claudication / Fontaine stage IIb (n=42/68%), rest pain / Fontaine III (n=9/15%) or ulcerations or gangrene / Fontaine stage IV (n=11/18%). (Table 1).
The severity of the iliac artery disease could be confirmed by a mean pain free walking distance of only 89m and a mean Ankle Brachial Index (ABI) on the affected side of 0.46.
Only patients with TASC II C (n=37 / 60%) and TASC II D (n=25 / 40%) classification of disease morphology were operated on.
Operative and postoperative results summary:
The 66 patients received either unilateral bypass reconstructions in n=40 (61%) or a cross-over bypass procedures in n= 26 (39%) of the cases.
30 day mortality was 4.5 % (n=3) and no graft infection has been recorded during the complete follow up period.
Postoperatively the ABI of the affected side improved significantly to 0.89 from 0.46 and the majority of patients were in Fontaine stage I and IIa at their last follow up visit. (Table 1). The primary and secondary patency rates at 12 and 24 month have been 88.9%/95.1 % and 88.9%/95.1% respectively. The Limb Salvage Rate was 98.4% at 12 and 24 month (Table 2).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
ABI of affected side improved significantly from 0.46 to 0.89.
Primary patency rate at 12 months: 89.4% (SE 4%) n = 51 at risk
Primary patency rate at 24 months: 89.4% (SE 4%) n = 19 at risk
Secondary patency rate at 12 months: 95.1% (SE 2.8%) n = 55 at risk
Secondary patency rate at 24 months: 95.1% (SE 2.8%) n = 20 at risk
Limb salvage rate at 12 months: 98.4% (SE 2.8%) n = 57 at risk
Limb salvage rate at 24 months: 98.4% (SE 2.8%) n = 22 at risk
30 day mortality was 4.5 % (n=3).
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Hemashield Woven Double Velour Vascular Graft (K954848)
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.3450 Vascular graft prosthesis.
(a)
Identification. A vascular graft prosthesis is an implanted device intended to repair, replace, or bypass sections of native or artificial vessels, excluding coronary or cerebral vasculature, and to provide vascular access. It is commonly constructed of materials such as polyethylene terephthalate and polytetrafluoroethylene, and it may be coated with a biological coating, such as albumin or collagen, or a synthetic coating, such as silicone. The graft structure itself is not made of materials of animal origin, including human umbilical cords.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Guidance Document for Vascular Prostheses 510(k) Submissions.”
0
SECTION 6: 510(k) SUMMARY
KIO308
| Submitter: | LeMaitre Vascular, Inc.
63 Second Avenue
Burlington, MA 01803 |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Andrew Hodgkinson
Vice President, Clinical and Regulatory Affairs
Phone: 781-221-2266 x108
Fax: 781-425-5049
Email: ahodgkinson@lemaitre.com |
| Date Prepared: | October 15, 2010 |
| Trade Name: | Albograft™ Vascular Prosthesis |
| Common Name: | Vascular Prosthesis |
| Classification Name: | Graft, vascular, synthetic/biologic composite |
| Predicate Device: | Hemashield Woven Double Velour Vascular Graft (K954848) |
| Device Description: | Albograft Vascular Prosthesis is a knitted/woven tubular polyester
fabric, impregnated with bovine collagen. |
| Intended Use: | The AlboGraft Double Velour Knitted and Woven Grafts are
indicated for use in the replacement or repair of arteries affected
with aneurysmal or occlusive disease. |
| Summary of
Technological
Characteristics: | AlboGraft Polyester Vascular Prosthesis is a knitted or woven
tubular polyester fabric, impregnated with bovine collagen. |
| Summary of Product
Testing: | The following tests have been performed per ISO 7198:
Burst Test
Longitudinal Tensile Strength
Radial Tensile Strength
Suture Pull-90°/45°
Wall Thickness
Integral Water Permeability
Visual Inspection
Usable Length
Relaxed Inner Diameter
Pressurized Inner Diameter |
| Summary of Pre-
clinical Study: | The biocompatibility of the device was tested per ISO10993-1. |
| Summary of
Retrospective
Clinical Review | Patient baseline data, preoperative risk factors, diagnosis and
secondary diseases:
Between Jan 1, 2007 and March 31, 2009, 66 consecutive patients have
received a surgical implant of a peripheral AlboGraft™ vascular
prosthesis in the iliac region (prox. anastomosis - common iliac artery /
distal anastomosis - proximal superficial femoral artery). The patients
consisted mainly of males (n= 44 / 66 %) with a mean age of 64.8 years
(Mean: H: 171 cm; W: 74 kg; BMI: 25.2 kg/cm²) and demonstrated typical |
:
.
1
| risk factors for development of illiac artery peripheral arterial occlusive
disease (pAOD).
The majority of patients (88%) suffered from arterial hypertension and
histories of smoking in 92% of the cases (73% of all patients are still
active smokers). Almost half (49 %) of the patients had additional
coronary heart disease , while additional risk factors like diabetes mellitus
or hyperlipidemia was only present in 9% or 3% of the patients
respectively. Chronic obstructive pulmonary disease was present in 29%
of the patients and cerebro vascular disease in n= 10 (15%) of which n=8
had a previous stroke. Also almost half of the patients (49%) had
| previous arterial reconstructions. | ||
|---|---|---|
| Disease / Diagnosis: | ||
| 4 patient suffered from aneurysmal disease (n=2 iliac artery aneurysms; | ||
| n=2 suture line aneurysms) and 62 patients reported pAOD of the iliac | ||
| artery with either severe claudication / Fontaine stage IIb (n=42/68%), | ||
| rest pain / Fontaine III (n=9/15%) or ulcerations or gangrene / Fontaine | ||
| stage IV (n=11/18%). (Table 1). | ||
| The severity of the iliac artery disease could be confirmed by a mean | ||
| pain free walking distance of only 89m and a mean Ankle Brachial Index | ||
| (ABI) on the affected side of 0.46. | ||
| Only patients with TASC II C (n=37 / 60%) and TASC II D (n=25 / 40%) | ||
| classification of disease morphology were operated on. | ||
| Operative and postoperative results summary: | ||
| The 66 patients received either unilateral bypass reconstructions in n=40 | ||
| (61%) or a cross-over bypass procedures in n= 26 (39%) of the cases. | ||
| 30 day mortality was 4.5 % (n=3) and no graft infection has been | ||
| recorded during the complete follow up period. | ||
| Postoperatively the ABI of the affected side improved significantly to 0.89 | ||
| from 0.46 and the majority of patients were in Fontaine stage I and IIa at | ||
| their last follow up visit. (Table 1). The primary and secondary patency | ||
| rates at 12 and 24 month have been 88.9%/95.1 % and 88.9%/95.1% | ||
| respectively. The Limb Salvage Rate was 98.4% at 12 and 24 month | ||
| (Table 2). | ||
| Table 1: Pre and Post Operative (last follow up visit) Fontaine stage | ||
| Classification for the n= 62 patients with Peripheral Arterial Disease | ||
| (pAOD). | ||
| Fontaine stage | Pre-Op (n=62) | Last follow up |
| visit (n=57) | ||
| I - asymptomatic | 0 (0.0%) | 39 (62.9%) |
| Ila- Lifestyle limiting | ||
| Intermitted Claudication (IC) | 0 (0.0%) | 11 (17.7%) |
| IIb - Severe Intermitted | ||
| Claudication (IC) | 42 (67.7%) | 7 (11.3%) |
| III - Restpain | 9 (14.5%) | 0 (0.0%) |
| IV - Ulcerations or Gangrene | 11 (17.7%) . | 0 (0.0%) |
11 - 11
.
2
| Table 2: Patency and Limb Salvage Rates in % analyzed by Kapla
| Meier Survival Analysis: | ||
|---|---|---|
| n = 66 patients (SE = Standard Error) | ||
| 12 month | 24 month | |
| Primary Patency | ||
| Rate | 89.4% | |
| (SE 4%) n = 51 at | ||
| risk | 89.4% | |
| (SE 4%) n = 19 at risk | ||
| Secondary | ||
| Patency Rate | 95.1% | |
| (SE 2.8%) n = 55 at | ||
| risk | 95.1% | |
| (SE 2.8%) n = 20 at risk | ||
| Limb Salvage | ||
| Rate | 98.4% | |
| (SE 2.8%) n = 57 at | ||
| risk | 98.4% | |
| (SE 2.8%) n = 22 at risk |
Vascular Prosthesis is substantially equivalent to the predicate Conclusion: device based on its indications for use and fundamental scientific technology. ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird symbol, with three curved lines representing the bird's body and wings. The bird is positioned to the right of the text. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" is arranged in a circular fashion around the bird symbol.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
LeMaitre Vascular, Inc. c/o Mr. Andrew Hodgkinson 63 Second Avenue Burlington, MA 01803
Re: K103080 AlboGraft Double Velour Knitted or Woven Vascular Prosthesis (Peripheral indication) Regulation Number: 21 CFR 870.3450 Regulation Name: Vascular Graft Prosthesis Regulatory Class: Class II Product Code: MAL Dated: October 18, 2010 Received: October 19, 2010
Dear Mr. Hodgkinson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
JAN 1 9 2011
4
Page 2 - Mr. Andrew Hodgkinson
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. .
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely vours,
Duma R. Kirchner
Bram D. Zuckerman, M.D. V Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Indications for Use
510(k) Number (if known): K103080
Device Name: _LeMaitre AlboGraft Double Velour Knitted or Woven Vascular Prosthesis (peripheral indication)
Indications For Use:
The AlboGraft Double Velour Knitted or Woven Vascular Prosthesis (peripheral indication) are indicated for use in the replacement or repair of arteries affected with aneurismal or occlusive disease.
Prescription Use
AND/OR
Over-The-Counter Use
(Part 21 CFR 801 Subpart D)
(21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
uma R. V. hmes
(Division Sign-Off) (Division of Cardiovascular Devices
510(k) Number_K 103080
Page 1 of ____________________________________________________________________________________________________________________________________________________________________